|Dr. Eric E. Poma Ph.D.||CEO, Chief Scientific Officer & Director||839.67k||N/A||1972|
|Ms. Jason S Kim||Pres & COO||600.41k||N/A||1975|
|Dr. Roger J. Waltzman M.B.A., M.D.||Chief Medical Officer||594.17k||N/A||1968|
|Mr. Sean McLennan||Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer||N/A||N/A||1971|
|Ms. Megan C. Filoon||Gen. Counsel & Sec.||N/A||N/A||N/A|
|Mr. Kurt Elster||Exec. VP of Corp. Devel.||N/A||N/A||1967|
|Dr. Jack Higgins Ph.D.||Exec. VP of Operations & Head of Manufacturing||N/A||N/A||1980|
|Dr. Erin Willert Ph.D.||Exec. VP of R&D||N/A||N/A||1982|
|Dr. Jen-Sing Liu Ph.D.||Exec. VP of Manufacturing||N/A||N/A||1963|
|Dr. Nenad Sarapa M.D., M.S.||Sr. VP of Clinical Devel.||N/A||N/A||N/A|
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Molecular Templates, Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 6; Compensation: 7.